Please assess the completion status of the following clinical trial:

Trial Title: Effect of Vitamin D as add-on Therapy for Vitamin D Insufficient Patients With Severe Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients, age ≥ 18 years~* A pulmonary specialist documented diagnosis of severe asthma according to the Global Initiative for Asthma and the German Asthma Network (GAN, www.german-asthma-net.de)~* Treatment with long-acting β2-agonists (LABA) and inhaled corticosteroids (ICS) at a dose of at least 1000 µg beclomethasone (or equivalent) per day, - chronic oral corticosteroid (OCS) use is allowed Stable asthma medication for ≥1 month prior to screening (≥4 months for omalizumab)~* Asthma Control Questionnaire (ACQ-5) score ≥ 1.5~* Vitamin D insufficiency as defined by a serum vitamin D concentration of \< 30 ng/ml but ≥ 10 ng/ml at screening~Exclusion Criteria:~* Patients on vitamin D substitution~* Current smokers or ex-smokers with a smoking history of more than 10 pack-years~* Pregnant or nursing women or women who intend to become pregnant during the study~* Known impaired renal function (GFR \< 30 ml/min) and history of physician-diagnosed nephrolithiasis~* Use of other investigational drugs during the study or within 30 days of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitamin D3 (Type: EXPERIMENTAL): Initial single dose 100000 IU, beginning from the second day 4000 IU/day for 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Amount of Placebo capsules corresponding to initial single dose of Vitamin D3, beginning from the second day amount of capsules corresponding to daily dose of Vitamin D for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).